Related Experiment Video

Updated: Jun 1, 2026

Real-time Digital Imaging of Leukocyte-endothelial Interaction in Ischemia-reperfusion Injury (IRI) of the Rat Cremaster Muscle
15:07

Real-time Digital Imaging of Leukocyte-endothelial Interaction in Ischemia-reperfusion Injury (IRI) of the Rat Cremaster Muscle

Published on: August 5, 2012

C-Reactive Protein: How Has JUPITER Impacted Clinical Practice?

Anil Verma1, Carl J Lavie, Richard V Milani

  • 1Department of Cardiology, Ochsner Clinic Foundation, New Orleans, LA.

Ochsner Journal
|May 24, 2011
PubMed

Insights

High-sensitivity C-reactive protein (hsCRP) indicates inflammation and predicts cardiovascular events. The JUPITER trial showed statin therapy reduced hsCRP, cardiovascular events, and mortality in primary prevention.

Area of Science:

  • Cardiology
  • Inflammation Research
  • Preventive Medicine

Background:

  • Inflammation is central to atherosclerosis development.
  • High-sensitivity C-reactive protein (hsCRP) is a key biomarker for inflammation and cardiovascular risk.
  • hsCRP assessment is clinically feasible and cost-effective for risk stratification.

Purpose of the Study:

  • To evaluate the impact of statin therapy on cardiovascular outcomes in primary prevention.
  • To investigate the role of hsCRP-guided statin use in reducing cardiovascular events.

Main Methods:

  • The JUPITER trial enrolled 17,802 healthy individuals with LDL cholesterol <130 mg/dL and hsCRP ≥2 mg/L.
  • Participants were randomized to receive rosuvastatin (20 mg daily) or placebo.
  • Outcomes included cardiovascular events and all-cause mortality.

Main Results:

  • Rosuvastatin significantly lowered hsCRP levels by 37%.
  • Statin treatment resulted in a 44% reduction in incident cardiovascular events.
  • A 20% reduction in all-cause mortality was observed in the rosuvastatin group.

Conclusions:

  • The JUPITER trial provides compelling evidence for statin therapy in primary cardiovascular prevention.
  • These findings highlight the link between inflammation, statin use, and the prevention of atherosclerotic cardiovascular disease.
  • The results support a shift in primary prevention strategies towards incorporating inflammation markers like hsCRP.

Keywords:
C-reactive proteinCardiovascular diseaseJUPITERcoronary artery diseaserisk factor

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Pericarditis II: Clinical Features and Diagnostic Tests01:19

Pericarditis II: Clinical Features and Diagnostic Tests

Pericarditis is distinguished by inflammation of the pericardium, the fibrous sac that encases the heart. It can be acute, lasting less than six weeks, or chronic, persisting for over three months. Understanding its clinical manifestations and diagnostic findings is crucial for timely and effective management.Clinical ManifestationsWhile pericarditis can be asymptomatic, it usually presents with characteristic symptoms such as:Chest Pain: The most characteristic symptom of pericarditis is chest...
Pericarditis III: Medical Management01:17

Pericarditis III: Medical Management

The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
Acute Pancreatitis II: Clinical Manifestations and Management01:30

Acute Pancreatitis II: Clinical Manifestations and Management

Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...